<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547050</url>
  </required_header>
  <id_info>
    <org_study_id>229844</org_study_id>
    <secondary_id>TWF 164-3020</secondary_id>
    <nct_id>NCT03547050</nct_id>
  </id_info>
  <brief_title>Rolandic Epilepsy Genomewide Association International Study</brief_title>
  <acronym>REGAIN</acronym>
  <official_title>Rolandic Epilepsy Genomewide Association International Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital JP Garrahan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aghia Sophia Children's Hospital of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Mutua de Terrassa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hasbro Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have discovered a small change in the genetic code which increases the risk of the
      brainwave abnormality that is found in rolandic epilepsy. We now wish to confirm this using a
      second much larger sample of patients. We will investigate the other genetic changes that
      cause people with the brainwave abnormality to develop seizures, as well as problems with
      speech, coordination, attention and learning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epilepsy is a common neurological disorder affecting 1% of the population. There are over 30
      types of epilepsy, some common, some rare. Most epilepsies arise in childhood and have a
      genetic cause. Approximately 25% of child patients have &quot;Rolandic Epilepsy&quot; or RE, also known
      as Benign Epilepsy with Centrotemporal Spikes (BECTS). RE has a complex genetic basis,
      probably made up of combinations of susceptibility variants in different genes. Children with
      RE quite often have other symptoms that affect their speech, attention, reading ability or
      coordination. The goal of this study is to find the genetic basis for susceptibility to
      seizures and associated comorbidities for RE using genomewide association approaches.

      We know that RE has a genetic basis and we recently discovered the genetic cause of the EEG
      pattern seen in RE. The goal of REGAIN is to now find the genetic basis for susceptibility to
      seizures and the associated symptoms above. Our hope is to be able to improve diagnosis and
      understand why each child with RE is different, and perhaps point us towards new treatments
      that are more effective and have fewer side effects.

      We will compare the genetic code of 3,000 children with RE against a similar number of people
      not affected by epilepsy. With the proposed large sample of participants, we will be able to
      pinpoint the exact changes that might lead to seizures or attention problems for example.
      Learning the genetic basis for these problems will deepen our understanding of the mechanisms
      and lead to new treatments or cures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Allelic association p value corrected for genome wide testing</measure>
    <time_frame>Day 1</time_frame>
    <description>We will look to see if there are changes in the genetic code that cause brainwave abnormalities close to the genetic changes that we have already discovered.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Rolandic Epilepsy</condition>
  <arm_group>
    <arm_group_label>Patients diagnosed with RE</arm_group_label>
    <description>People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>People without a lifetime history of seizures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.</description>
    <arm_group_label>Patients diagnosed with RE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Existing samples</intervention_name>
    <description>Control DNA samples will be used that have been previously acquired in other studies.</description>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Target population is 3,000 participants with a diagnosis of Rolandic Epilepsy (1,000 UK).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Rolandic Epilepsy in accordance with the following international
             criteria:

               -  Age of first afebrile seizure 3-12 years

               -  Seizures comprising focal sensorimotor seizures affecting the vocal tract and
                  face, with or without involvement of the arm

               -  Predominant sleep-related seizures

               -  EEG interictal centro-temporal spikes with normal background

          2. Current age 6-25 years

        Exclusion Criteria:

          1. No history of focal seizure

          2. Normal EEG or abnormal background features on EEG

          3. Known structural causes (stroke, tuberous sclerosis, infection, post-infectious or
             metabolic)

          4. Primary diagnosis of autism or global learning disability

          5. Focal central neurological deficit on clinical exam,

          6. Unable to provide informed consent

          7. Unable to provide blood sample
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Professor Deb K Pal, MA MSc PhD MRCP</last_name>
    <phone>+44 (020) 7848 5162</phone>
    <email>amber.collingwood@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Collingwood, MA</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Cigdem Akman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hasbro Children's Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Professor David Mandelbaum</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Professor Edward Novotny</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Juan P. Garrahan Children's Hospital</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C 1245</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Roberto Caraballo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Kids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 0A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Lisa Strug</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aghia Sophia Children's Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Professor Thanis Covanis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sicilian Epilepsy Network</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Professor Martino Ruggieri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Commissione Genetica Lega Italiana contro l'Epilepssia</name>
      <address>
        <city>Roma</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Pasquale Striano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Barcelona</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Yaiza Hernandez-Vega</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiff University School of Medicine</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Frances Gibbon</last_name>
    </contact>
    <contact_backup>
      <last_name>Dr Khalid Hamandi</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr John Jackman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 8RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Professor Deb K Pal, MA MSc PhD MRCP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swansea University College of Medicine</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Khalid Hamandi</last_name>
    </contact>
    <contact_backup>
      <last_name>Dr Frances Gibbon</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://childhoodepilepsy.org</url>
    <description>Childhood Epilepsy website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Rolandic</keyword>
  <keyword>Genetics</keyword>
  <keyword>Genomewide Association Study</keyword>
  <keyword>RE</keyword>
  <keyword>Neurology</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Rolandic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

